Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: Differential diagnosis

APMIS

Volumn 115, Issue 6, 2007, Pages 726-735

  Çomunoǧlu, Nil Üstündaǧ ^a   Durak, Haydar ^b   Çomunoǧlu, Cem ^c   Ekici, A Işin Doǧan ^a   Özkan, Ferda ^a   Akyildiz, Elif Ülker ^b   Ilvan, Şennur ^b   Calay, Zerrin ^b   Molinas, Nil ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Department of Pathology   (Turkey)

Author keywords

c kit; COX 2; Immunohistochemistry; Smooth muscle tumors; Uterus

Indexed keywords

BIOCHEMICAL MARKER; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOMA; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS TUMOR;

CYCLOOXYGENASE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SMOOTH MUSCLE TUMOR; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 34249796087     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2007.apm_629.x     Document Type: Article

References (38)

1. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001 32 : 984 7.
2. Clement PB. The pathology of uterine smooth muscle tumors and mixed endometrial stromal-smooth muscle tumors: a selective review with emphasis on recent advances. Int J Gynecol Pathol 2000 19 : 39 55.
3. Zaloude CJ, Hendrickson MR. Mesenchymal tumors of the uterus. In : Kurman RJ editor. Blaustein's Pathology of the Female Genital Tract. New York : Springer Verlag, 2002 : 561 615.
4. Al-Nafussi A. Uterine smooth-muscle tumours: practical approach to diagnosis. Curr Diagn Pathol 2004 10 : 140 56.
5. Gokaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest 2005 59 : 36 40.
6. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril 2004 81 : 1062 6.
7. Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999 18 : 20 8.
8. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998 12 : 1063 73.
9. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998 11 : 728 34.
10. Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol 2005 96 : 159 67.
11. Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O'Meara AT, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003 90 : 402 6.
12. Raspollini MR, Paglierani M, Taddei GL, Villanucci A, Amunni G, Taddei A. The protooncogene c-KIT is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2004 93 : 718.
13. McElroy DA. Connective Tissue. In : Prophet EB, Mills B, Arrington JB, Sobin LH editors. Armed Forces Institute of Pathology: Laboratory Methods in Histotechnology. Washington D.C. : American Registry of Pathology, 1992 : 135 6.
14. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol 1990 94 : 247 54.
15. Kir G, Cetiner H, Karateke A, Gurbuz A, Bulbul D. Utility of MIB-1 and estrogen and progesterone receptor in distinguishing between endometrial stromal sarcomas and endometrial stromal nodules, highly cellular leiomyomas. Int J Gynecol Cancer 2005 15 : 337 42.
16. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004 22 : 4514 22.
17. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999 74 : 196 201.
18. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Histopathology 2006 48 : 563 8.
19. Zaloudek C, Norris HJ. Mesenchymal tumors of the uterus. In : Kurman RJ editor. Blaustein's Pathology of the Female Genital Tract. New York : Springer Verlag, 1994 : 488 500.
20. Buttram VC Jr., Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981 36 : 433 45.
21. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989 160 : 637 41.
22. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003 23 : 729 32.
23. Soper JT, McCarty KS Jr., Hinshaw W, Creasman WT, McCarty KS Sr., Clarke-Pearson DL. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol 1984 150 : 342 8.
24. Akhan SE, Yavuz E, Tecer A, İyibozkurt CA, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas: A clinicopathologic study. Gynecol Oncol 2005 99 : 36 42.
25. Raspollini MR, Amunni G, Villanucci A, Paglierani M, Taddei GL. Cyclooxygenase-2 expression in uterine leiomyosarcomas. J Chemother 2004 16 : 577 81.
26. Matsumoto Y, Ishiko O, Sumi T, Yoshida H, Deguchi M, Nakagawa E, et al. Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions. Oncol Rep 2001 8 : 1225 7.
27. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 2003 25 : 282 5.
28. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 279 : 577 80.
29. Oliva E, Young RH, Amin MB, Clement PB. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002 26 : 403 12.
30. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003 22 : 181 4.
31. Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, et al. Imatinib mesylate (gleevec)-targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 2005 13 : 167 70.
32. Serrano C, Mackintosh C, Herrero D, Martins AS, Hernandez T, Perez-Fontan J, et al. Imatinib is not a potential alternative treatment for uterine leiomyosarcoma. Clin Cancer Res 2005 11 : 4977 9.
33. Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O, et al. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol 2006 25 : 70 6.
34. Hornick JL, Fletcher CDM. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002 117 : 188 93.
35. Winter WE III., Seidman JD, Krivac TC, Chauhan S, Carlson JW, Rose GS, et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003 91 : 3 8.
36. Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-kit. Gynecol Oncol 2003 91 : 9 14.
37. Raspollini MR, Amunni G, Villanucci A, Pinzani P, Simi L, Paglierani M, et al. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment. Clin Cancer Res 2004 10 : 3500 3.
38. Ciontea SM, Radu E, Regalia T, Ceafalan L, Cretoiu D, Gherghiceanu M, et al. C-kit immunopositive interstitial cells (Cajal-type) in human myometrium. J Cell Mol Med 2005 9 : 407 20.